Combination treatment of flag with non-pegylated liposomal doxorubicin (myocet™) in elderly patients with acute myeloid leukemia: A single center experience

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 3, 2011, Pages 703-709

  Melillo, Lorella ^a   Valente, D ^a   D'Arena, G ^a   Dell'Olio, M ^a   Falcone, A ^a   Minervini, M M ^a   Nobile, M ^a   Rossi, G ^a   Sanpaolo, G ^a   Scalzulli, P R ^a   Cascavilla, N ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Elderly FLAG Myocet combination

Indexed keywords

CYTARABINE; DOXORUBICIN; FLUDARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTIBIOTIC AGENT; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BONE MARROW HYPOPLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; TREATMENT OUTCOME; ACUTE MYELOBLASTIC LEUKEMIA; ANTIBIOTIC THERAPY; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GERIATRIC PATIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LIPOSOMAL DELIVERY; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; ORAL MUCOSITIS; PERIPHERAL BLOOD STEM CELL;

EID: 80055107984     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400316     Document Type: Article

References (25)

1. Estey E. AML in older patients: are we making progress? Best Pract Res Clin Haematol 2009; 22:529-36.
2. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17:3569-76. (Pubitemid 29517929)
3. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106:27-34. (Pubitemid 40967170)
4. Harousseau JL. Acute myeloid leukemia in the elderly. Blood Rev 1998; 12:145-53.
5. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108:3280-88.
6. Stone RM. Postremission therapy in adults with acute myeloid leukemia. Semin Hematol 2001; 38:17-23. (Pubitemid 32717671)
7. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon. J Clin Oncol 1998; 16:872-81. (Pubitemid 28115455)
8. Jehn U, Suciu S, Thomas X, et al. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia 2006; 20:1723-30. (Pubitemid 44590960)
9. Thomas X, Suciu S, Rio B, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Hematologica 2007; 92:389-96. (Pubitemid 350143549)
10. Montillo M, Tedeschi A, Pagano L, et al. Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the GIMEMA Group. Br J Hematol 2000; 111:334-37.
11. Gorin NC, Labopin M, Pichard P, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Hematol 2000; 110:887-93.
12. Ferrara F, Venditti A, Carellajr AM, et al. Autologous stem cell transplantation for patients with acute myeloid leukemia aged over 60 yr. Eur J Hematol 2002; 69:200-204. (Pubitemid 35448124)
13. Oriol A, Ribera JM, Esteve J, et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Hematologica 2004; 89:791-800. (Pubitemid 38986951)
14. Clavio C, Canara P, Miglino M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Hematologica 1996; 81:513-20.
15. Carella AM, Cascavilla N, Greco MM, et al. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (FLAG regimen): a single center study. Leuk Lymphoma 2001; 40:295-303. (Pubitemid 32401386)
16. Ferrara F, D'Arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Hematologica 2005; 90:776-84. (Pubitemid 40897219)
17. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008; 113:3181-85.
18. Visani G, Isidori A. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther 2009; 9:357-63.
19. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33:2-7. (Pubitemid 43866214)
20. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13:2827-34.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute of the myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-25.
22. Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single center experience. Ann Hematol 2003; 82:231-35. (Pubitemid 36701015)
23. Cascavilla N, D'Arena G, Greco MM, Melillo L, Merla E, Carella AM. Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia. 2008 Br J Hematol 2008; 142:845-56.
24. Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010; 115:2586-91.
25. Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Hematol 2008; 143:681-89.